Skip to main content
Premium Trial:

Request an Annual Quote

Ventana to Develop CDx for Genmab Cancer Drug

NEW YORK (GenomeWeb News) – Roche business Ventana today announced a companion diagnostic development deal for a Genmab antibody drug conjugate program.

Ventana will develop an immunohistochemistry CDx test for detecting tissue factor in patient tumor samples with the intent that the assay could be used as the screening test in clinical trials for Genmab's HuMax-TF-ADC, Ventana said.

HuMax-TF-ADC is being developed for the treatment of solid cancers, and last summer Genmab filed an investigational new drug application with the US Food and Drug Administration to start a dose escalation trial of HuMax-TF-ADC to treat multiple solid tumors.

Financial and other terms of today's agreement were not disclosed.

The deal is the latest CDx agreement inked by Ventana, which noted that it is currently involved in more than 180 collaborations to develop and commercialize such assays. Last month, it extended an existing CDx agreement with Bayer Pharma for the drug firm's targeted therapy projects.